MARKET

CABA

CABA

Cabaletta Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.68
-0.09
-0.76%
Closed 16:29 09/18 EDT
OPEN
11.96
PREV CLOSE
11.77
HIGH
12.14
LOW
11.68
VOLUME
302.33K
TURNOVER
--
52 WEEK HIGH
19.63
52 WEEK LOW
5.51
MARKET CAP
280.78M
P/E (TTM)
-10.8148
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cabaletta Bio Announces Publication of Comprehensive Preclinical Study Results for DSG3-CAART in Pemphigus Vulgaris
* DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgaris * Soluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy and did not demonstrate off-target toxicity * DesCAARTes™ Phase 1 clinical trial actively recruiting
GlobeNewswire · 08/25 13:00
Cabaletta Bio Highlights Publication Of Comprehensive Preclinical Study Results For DSG3-CAART In Pemphigus Vulgaris
DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgaris Soluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy and did not
Benzinga · 08/25 12:07
Cabaletta Bio EPS beats by $0.04
Cabaletta Bio (NASDAQ:CABA): Q2 GAAP EPS of -$0.35 beats by $0.04. Cash, equivalents and investments of $123.2M. Shares -2.29% PM. Press Release
seekingalpha · 08/06 18:13
Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update
PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today anno
GlobeNewswire · 08/06 11:30
Cabaletta Bio to Present at Multiple August Investor Conferences
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today anno
GlobeNewswire · 08/03 12:00
Morgan Stanley Maintains Overweight on Cabaletta Bio, Raises Price Target to $20
Morgan Stanley maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $19 to $20.
Benzinga · 07/15 14:05
Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies
GlobeNewswire · 07/07 13:00
Cabaletta Bio, Artisan Bio Announce Gene Editing Research, Collaboration Agreement To Develop Next-Gen CAAR T Cell Therapies
Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc.
Benzinga · 07/07 12:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CABA stock price target is 22.50 with a high estimate of 25.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 59
Institutional Holdings: 16.51M
% Owned: 68.67%
Shares Outstanding: 24.04M
TypeInstitutionsShares
Increased
24
1.09M
New
17
293.87K
Decreased
5
907.96K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Director
Steven Nichtberger
Chief Financial Officer
Anup Marda
Executive Vice President
Gwendolyn Binder-Scholl
General Counsel
J. Brian Stalter
Other
David Chang
Independent Director
Catherine Bollard
Independent Director
Brian Daniels
Independent Director
Richard Henriques
Independent Director
Mark Simon
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average CABA stock price target is 22.50 with a high estimate of 25.00 and a low estimate of 20.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CABA
Cabaletta Bio Inc. is a clinical stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cabaletta Bio Inc stock information, including NASDAQ:CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.